A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy.
Fibrates either alone or in combination with statins have been commonly used for the treatment of high non-HDL-cholesterol levels. In addition, this type of therapy is also associated with some adverse events like rhabdomyolysis. We present the first case in the literature describing the development of both rhabdomyolysis-induced acute renal failure and thromboembolic event under the treatment of fibrate monotherapy.
Yildiz
Abdulkadir
A
Department of Cardiology, Yuksek Ihtisas Heart-Education and Research Hospital, Ankara, Turkey.
Gucuk
Esra
E
Cay
Serkan
S
D058186:Acute Kidney Injury / Q000209:etiology*; D000368:Aged; D002995:Clofibric Acid / Q000009:adverse effects*; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008297:Male; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000150:complications; D012307:Risk Factors; D013923:Thromboembolism / Q000139:chemically induced*
D000960:Hypolipidemic Agents; D002995:Clofibric Acid